Fennec Pharmaceuticals Inc. (FENC) Stock Forecast
FENC analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.67 / 5 from 6 analysts
- Price target
- $17.67 average of analyst targets
- Upside to target
- +77.0% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $0.09
- 52-week range
- $5.77 – $12.78
FENC analyst ratings
6 analystsNumber of analysts at each rating.
FENC price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
FENC earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.11 | $0.06 | $0.16 | −$0.02 | +630.0% | 5 |
| Current fiscal year (2026) | $0.32 | $0.20 | $0.52 | −$0.28 | +213.9% | 5 |
| Next fiscal year (2027) | $0.95 | $0.63 | $1.42 | $0.32 | +194.4% | 5 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
FENC revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $18.9M | $18.2M | $19.6M | +51.7% | 6 |
| Current fiscal year (2026) | $72.6M | $71.0M | $74.0M | +62.5% | 6 |
| Next fiscal year (2027) | $103.1M | $90.7M | $108.5M | +42.1% | 6 |
FENC EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
FENC revenue: reported and forecast
FENC EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.11 | $0.11 | $0.11 | $0.11 | $0.11 | −5.4% | 1 up · 2 down |
| Current fiscal year (2026) | $0.30 | $0.30 | $0.30 | $0.33 | $0.32 | +8.8% | 4 up · 1 down |
| Next fiscal year (2027) | $0.89 | $0.89 | $0.89 | $0.95 | $0.95 | +6.5% | 3 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
FENC earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; FENC beat in 6 of 12.
What analysts expect from FENC
6 analysts cover Fennec Pharmaceuticals; their consensus rating is strong buy (4.67 on a 1–5 scale, where 5 is a strong buy). The average price target is $17.67, 77.0% above the latest close of $9.98. Analysts expect earnings of $0.32 per share for 2026, +213.9% from a year earlier. For 2027 the average estimate is $0.95 per share on revenue of $103.1 million. Fennec Pharmaceuticals beat the EPS estimate in 6 of the last 12 quarters.
Related: FENC income statement, FENC key metrics, FENC chart. See the FENC stock overview for the latest quote and news.
FENC forecast FAQ
What is Fennec Pharmaceuticals's price target?
The average analyst price target for Fennec Pharmaceuticals is $17.67, 77.0% above the latest close of $9.98.
Is Fennec Pharmaceuticals a buy, hold or sell?
Of 6 analysts covering Fennec Pharmaceuticals, 4 rate it a strong buy, 2 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Fennec Pharmaceuticals's EPS forecast?
Analysts forecast $0.32 per share for 2026 (range $0.20 to $0.52); for 2027 the estimate is $0.95.
What is Fennec Pharmaceuticals's revenue forecast?
The average revenue estimate for 2026 is $72.6 million, growth of 62.5%; for 2027 it is $103.1 million.
When does Fennec Pharmaceuticals report earnings?
Fennec Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 before the market opens; the EPS estimate is $0.09.
Does Fennec Pharmaceuticals usually beat earnings estimates?
Fennec Pharmaceuticals reported EPS at or above the analyst estimate in 6 of the last 12 quarters.